Preclinical Checkpoint Therapy Development for Cancer Vaccines

Synergizing "Seeds" and "Water" to break through the immune-suppressive TME. Creative Biolabs offers specialized preclinical development of immunological checkpoint therapies designed to maximize the efficacy of cancer vaccines.

Our solutions bridge the gap between immune priming and sustained effector function. By integrating next-generation immune checkpoint inhibitors (ICIs) with personalized tumor vaccines, we help turn "cold" tumors into highly reactive "hot" immune landscapes.

Consult Our Experts

The Synergy Strategy: Why Combine Vaccines with ICIs?

Developing a successful cancer vaccine is only half the battle. Without addressing the "brakes" of the immune system, even the most potent vaccine can fail. Our solution focuses on three critical preclinical dimensions:

▶ Seed-Water Dynamics: Vaccines act as the "seed" to induce specific T cells, while ICIs act as "water" to maintain their functional state within the tumor microenvironment (TME).
▶ Breaking T-cell Exclusion: For "cold" tumors, vaccines are essential to drive T-cell infiltration, which is then released from suppression by 2nd generation ICIs (e.g., anti-TIGIT, anti-LAG3).
▶ Treg Depletion: Eliminating regulatory T cells (Tregs) to remove the dominant immunosuppressive barrier, significantly amplifying the vaccine-induced effector response.

Specialized Development Solutions

We provide a fully integrated preclinical suite to evaluate and optimize combination immunotherapies:

2nd Gen ICI Discovery

Screening and validation of novel checkpoint modulators targeting TIGIT, LAG-3, VISTA, and OX40 to provide superior synergy with tumor antigen vaccines.

Treg Depletion Strategies

Developing specific monoclonal antibodies or small molecules to selectively deplete or reprogram immunosuppressive Treg cells within the TME.

Deep TME Characterization

Quantitative mapping of the "cold-to-hot" transition using multi-color flow cytometry and spatial transcriptomics to visualize immune cell infiltration.

Synergy Validation Models

Utilizing CT26 (Hot) and TC1 (Cold) murine models to benchmark the performance of one-shot vaccination plus checkpoint modulation.

Request Project Blueprint

Agile Preclinical Development Workflow

Our systematic pipeline ensures every combination therapy is optimized for biological stability and protective potency:

Step 1: Checkpoint Target Screening & Design

Activities: Bioinformatic identification of upregulated checkpoints in specific tumor models. We design 2nd gen ICIs and Treg depletion agents optimized for synergy with the target antigen's MHC-binding profile.

Outcome: Selection of high-affinity modulators and preliminary structural verification.

Step 2: In Vitro Immune Cell Activation Assays

Activities: Evaluating the enhancement of T-cell proliferation and IFN-γ secretion when vaccine-primed APCs are co-cultured with ICI candidates. We measure the relief of T-cell exhaustion markers (PD-1, TIM-3).

Outcome: Functional proof-of-concept for combination synergy in vitro.

Step 3: TME Characterization & Modeling

Activities: Profiling of CT26 (Hot) vs. TC1 (Cold) tumor microenvironments using sequencing and spatial transcriptomics. Identifying the dominant suppression barriers (e.g., high Treg density or TGF-β signaling).

Outcome: A customized TME map guiding the selection of either ICI-only or Vaccine+ICI strategies.

Step 4: In Vivo Efficacy & Infiltration Analysis

Activities: Longitudinal tracking of tumor growth inhibition. We perform multiplex IF and IHC on tumor sections to quantify the infiltration of CD8+ TILs and the depletion efficiency of FOXP3+ Tregs.

Outcome: Quantitative data on the "Cold-to-Hot" transformation and antitumor efficacy.

Step 5: Optimization & Lead Selection

Activities: Refining the "Seed and Water" ratio—optimizing the dosing frequency of the vaccine and ICI. We evaluate long-term immunological memory and protection against tumor rechallenge.

Outcome: A comprehensive preclinical report supporting IND-enabling studies.

Discuss Your Development Timeline

Proprietary Technology Platforms

Our solutions are powered by specialized platforms designed for the unique challenges of combination immunotherapy:

Checkpoint-Select Analytics: A robust discovery platform for 2nd generation ICIs. We utilize high-throughput screening to identify antibodies that not only block inhibitory receptors but also enhance the cross-presentation efficiency of tumor vaccines.

Validated panels for TIGIT, LAG-3, VISTA, and B7-H3
Species-specific (murine/canine/non-human primate) cross-reactivity testing
Fc-engineering to modulate ADCC activity for Treg depletion

TME-Insight Spatial Mapper: An advanced analytical suite combining multiplex immunofluorescence (mIF) and spatial transcriptomics. This platform allows us to visualize the spatial distribution of vaccine-induced T cells relative to ICI treatment.

Simultaneous tracking of up to 9 immune markers (e.g., CD8, Granzyme B, FOXP3)
Analysis of the "Immune Desert" vs. "Immune Excluded" architectures
Correlation of spatial metrics with overall antitumor efficacy

Cold-to-Hot Modeling Suite: A specialized library of syngeneic murine models with well-characterized immune landscapes. We provide "Cold" tumor models (like TC1) specifically to test the necessity of vaccine-priming for ICI success.

Established CT26, B16-F10, and TC1 baseline TME profiles
Humanized mouse models for testing human-specific ICIs
Orthotopic modeling for organ-specific TME evaluation

Checkpoint-Select

TME-Insight

Cold-to-Hot Models

Scientific Insight: Optimizing the "Seed and Water" Strategy

Size Tuning & Combination Synergy (Wang et al., 2024)

Innovation: Research published in Pharmaceutics highlights the importance of TME characterization in determining the success of combination therapies. The study utilized the "Seed and Water" analogy to guide immunotherapy development.

Research Highlights:

Cold Tumor Rescue: In "Cold" models (TC1), ICIs alone failed. Robust T-cell infiltration was only achieved by combining ICIs with a specific tumor antigen vaccine (the "Seed").
Treg Depletion: Depleting regulatory T cells was identified as a critical factor in enhancing the long-term anti-tumor effect of the vaccine.
ICI Sustainability: 2nd Gen ICIs (e.g., anti-TIGIT) acted as "Water," maintaining the functional vigor of infiltrated T cells to prevent exhaustion.

Size-tuned mesoporous silica adjuvant for one-shot long-term anti-tumor vaccination.

Fig.1 Size tuning of mesoporous silica adjuvant for one-shot vaccination with long-term anti-tumor effect.^1,2

Frequently Asked Questions

Q: What is the main advantage of 2nd gen ICIs like anti-TIGIT in vaccine development?

A: Unlike 1st gen PD-1/CTLA-4 blockers, 2nd gen checkpoints like TIGIT are often co-expressed on highly functional TILs. When combined with vaccines, they target the specific exhaustion pathways that limit vaccine-induced T cells, providing a more refined and potent synergistic effect.

Q: Why is Treg depletion necessary for Cold tumors?

A: Cold tumors are often defined by a high ratio of Tregs to CD8+ T cells. Even if a vaccine induces new T cells, they are suppressed upon entry. Our Treg depletion solutions remove this physical and chemical barrier, allowing vaccine-primed T cells to execute their effector functions.

Q: Can Creative Biolabs customize models for specific organ-targeted vaccines?

A: Yes. We offer orthotopic tumor models (e.g., lung, liver, brain) that more accurately reflect the tissue-specific immune suppression of the TME, which is crucial for evaluating how checkpoints and vaccines interact in a biologically relevant environment.

Q: Do you offer help with the sequencing of ICI and Vaccine administration?

A: Absolutely. Timing is critical (e.g., priming with the vaccine before releasing the brakes with ICIs). Our preclinical studies include dosing optimization protocols to determine the most effective "Seed then Water" or "Simultaneous" schedules.

Q: What readouts do you provide for the Cold-to-Hot transition?

A: We provide high-resolution data including TIL density (via flow/IHC), spatial transcriptomic profiles, cytokine signatures (IFN-γ/IL-12), and the CD8/Treg ratio, offering a complete picture of the immune landscape transformation.

Related Resources

References:
1. Wang, Xiupeng, Yu Sogo, and Xia Li. "Size Tuning of Mesoporous Silica Adjuvant for One-Shot Vaccination with Long-Term Anti-Tumor Effect." Pharmaceutics 16.4 (2024): 516.
2. Distributed under Open Access License CC BY 4.0, without modification.